tbuckley/cabot-search huggingface dataset:
Abstract 465: G3BP1 Supports Osteogenic Mitochondrial Antiviral Signaling - NFAT Transcriptional Relays in Aortic Vascular Smooth Muscle Cells
Authors: Austin T Gay, Bindu Ramachandran, John N Stabley, Su-Li Cheng, Abraham Behrmann, Li Li, Megan Mead, Bart O Williams, Zhijian Chen, Dwight A Towler
Journal: Circulation Research (2017)

In vascular smooth muscle (VSM), LRP6, a Wnt co-receptor, inhibits arteriosclerotic noncanonical Wnt signals that activate protein arginine (Arg) methylation relays, converging on nuclear factor of activated T cells (NFAT). LRP6 deletion in VSM increases arteriosclerotic calcification and stiffness in low density lipoprotein receptor (LDLR)-deficient mice fed diabetogenic diets. To study how Arg methylation mediates LRP6 actions, immunoaffinity mass spectrometry was performed on aortic VSM cell extracts from SM22-Cre;LRP6(fl/fl);LDLR-/- and LRP6(fl/fl);LDLR-/- mice. LRP6 deficiency altered Arg methylation of over 490 proteins, but only 22 exhibited increased monomethylation (MMA) with reduced dimethylation. One protein involved in atherosclerosis, G3BP1, exhibited a &gt;30-fold increase in MMA of its C-terminal domain with LRP6 deficiency. Co-transfection confirmed that protein Arg methyltransferase 1 modified G3BP1 and was inhibited by LRP6. G3BP1 stimulated Frizzled-dependent NFAT transcription, again inhibited by LRP6. Nuclear NFATc4 and NFATc4 association with osteopontin (OPN) and alkaline phosphatase (TNAP) chromatin increased in LRP6-deficient VSM, and was reduced with G3BP1 deficiency. G3BP1 activation of NFAT required its nuclear transport domain and the MMA modified C-terminal domain to respond to Ddx58 - a modulator of mitochondrial antiviral signaling (MAVS) linked to aortic calcification. Ddx58 colocalized and synergized with G3BP1 in VSM to upregulate targets of noncanonical signaling, including OPN and TNAP. While VSM LRP6 deficiency increased Ddx58 levels, G3BP1 insufficiency reduces Ddx58 and osteogenic expression. RNAi targeting G3BP1, Ddx58 or NFATc4 reduced VSM osteogenic programs; VSM from MAVS-deficient mice exhibited reduced TNAP activity and osteogenic gene expression. Mass spectrometry data indicates that G3BP1 and Ddx58 form complexes with specific nucleoporins regulating nucleocytoplasmic transport. Thus, G3BP1 is a target of MMA regulated by LRP6. G3BP1 promotes osteogenic signals in VSM, conveyed by a MAVS relay to regulate osteogenic transcription. Targeting G3BP1 and protein Arg methyltransferases may mitigate arteriosclerotic calcification in type 2 diabetes.
Queries and Minor Notes
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Authors: John A. Bittl, Usman Baber, Steven M. Bradley, Duminda N. Wijeysundera
Journal: Journal of the American College of Cardiology (2016)
Companies Scaling Back IDO1 Inhibitor Trials
Journal: Cancer Discovery (2018)

Based on negative results of the ECHO-301 trial in melanoma, as well as in the pancreatic cancer cohort of ECHO-203, Incyte halted several trials of its IDO inhibitor epacadostat. Other companies, including NewLink Genetics and Bristol-Myers Squibb, also decided to scale back and/or halt trials of their IDO inhibitors. However, researchers offered reasons for the disappointing trial results and said that trials of IDO inhibitors should not be abandoned.
ACCF/AHA Methodology for the Development of Quality Measures for Cardiovascular Technology
Authors: Robert O. Bonow, Pamela S. Douglas, Alfred E. Buxton, David J. Cohen, Jeptha P. Curtis, Elizabeth DeLong, Joseph P. Drozda, T. Bruce Ferguson, Paul A. Heidenreich, Robert C. Hendel, Frederick A. Masoudi, Eric D. Peterson, Allen J. Taylor
Journal: Journal of the American College of Cardiology (2011)
A Text-Book of Pathology.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults
Authors: Simon Finfer, Sharon Micallef, Naomi Hammond, Leanlove Navarra, Rinaldo Bellomo, Laurent Billot, Anthony Delaney, Martin Gallagher, David Gattas, Qiang Li, Diane Mackle, Jayanthi Mysore, Manoj Saxena, Colman Taylor, Paul Young, John Myburgh
Journal: New England Journal of Medicine (2022)

Whether the use of balanced multielectrolyte solution (BMES) in preference to 0.9% sodium chloride solution (saline) in critically ill patients reduces the risk of acute kidney injury or death is uncertain.
Brief Report: Gastroenteritis Among Attendees at a Summer Camp—Wyoming, June-July 2006
Journal: JAMA (2007)

On July 19, 2006, the Environmental Protection Agency (EPA) notified the Wyoming Department of Health (WDH) of an Escherichia coli-positive well-water sample, indicating fecal contamination, that had been submitted from a Wyoming summer youth camp after the camp manager noticed cases of gastroenteritis among campers and staff members. This report describes the subsequent investigation by WDH, the Wyoming Department of Agriculture (WDA), and the Wyoming Department of Environmental Quality (WDEQ), which identified Norovirus and Campylobacter species as the etiologic agents.
Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial
Authors: Xiao-Yun Li, Dong-Hua Luo, Ling Guo, Hao-Yuan Mo, Rui Sun, Shan-Shan Guo, Li-Ting Liu, Zhen-Chong Yang, Jin-Hao Yang, Fang Qiu, Xue-Song Sun, Pan Wang, Qing Liu, Ji-Bin Li, Qing-Nan Tang, Chao Lin, Qi Yang, Sai-Lan Liu, Yu-Jing Liang, Guo-Dong Jia, Dong-Xiang Wen, Chun-Yan Guo, Jin-Jie Yan, Chong Zhao, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
Journal: Journal of Clinical Oncology (2022)

Cumulative doses of 200 mg/m2 for concurrent cisplatin (DDP) were indicated by retrospective studies as sufficient in conferring survival benefit for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We performed an open-label, phase II, randomized, controlled trial to test the noninferiority of a two-cycle 100 mg/m2 concurrent DDP regimen over three-cycle in patients with low-risk LA-NPC with pretreatment Epstein-Barr virus DNA levels < 4,000 copies/mL.Eligible patients were randomly assigned 1:1 to receive two cycles or three cycles concurrent DDP-based chemoradiotherapy. The primary end point was 3-year progression-free survival (PFS). The secondary end points included overall survival, distant metastasis-free survival, locoregional relapse-free survival, etc.Between September 2016 and October 2018, 332 patients were enrolled, with 166 in each arm. After a median follow-up of 37.7 months, the estimated 3-year PFS rates were 88.0% in the two-cycle group and 90.4% in the three-cycle group, with a difference of 2.4% (95% CI, -4.3 to 9.1, Pnoninferiority = .014). No differences were observed between groups in terms of PFS, overall survival, and the cumulative incidences of locoregional relapse and distant metastasis. Patients in the three-cycle group developed significantly more grade 3-4 mucositis (41 [24.8%] v 25 [15.1%]), hyponatremia (26 [15.8%] v 14 [8.4%]), and dermatitis (9 [5.5%] v 2 [1.2%]). The overall all-grade and grade 3-4 toxicity burdens were heavier in three-cycle group (T-scores, 12.33 v 10.57, P < .001 for all grades; 1.76 v 1.44, P = .05 for grade 3-4). Patients in the three-cycle group also showed more all-grade hearing impairment, dry mouth and skin fibrosis, and impaired long-term quality of life.Intensity-modulated radiotherapy plus two cycles of concurrent 100 mg/m2 DDP could be an alternative treatment option for patients with low-risk LA-NPC.
New Cancers in People Who Have Had Bone Marrow Transplants
Journal: Annals of Internal Medicine (1999)

Summaries for Patients16 November 1999New Cancers in People Who Have Had Bone Marrow TransplantsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-10-199911160-00042 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Bone marrow transplant is a type of treatment for some kinds of cancer. It involves giving chemotherapy or radiation treatment to destroy a patient's bone marrow, which is producing cancerous cells, then replacing the bone marrow with bone marrow from a healthy person. Unfortunately, people who have had bone marrow transplants as treatment for cancer seem to be at risk for additional cancers in the future. This may be because of damage from the radiation and chemotherapy.Why did the researchers do this particular study?The researchers wanted ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation.” It is in the 16 November 1999 issue of Annals of Internal Medicine (volume 131, pages 738-734). The authors are H.J. Kolb, G. Socié, T. Duell, M.T. Van Lint, A. Tichelli, J.F. Apperley, E. Nekolla, P. Ljungman, N. Jacobsen, M. van Weel, R. Wick, M. Weiss, and H.G. Prentice, for the Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMalignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation H. J. Kolb , Gérard Socié , Thomas Duell , Maria Theresa Van Lint , André Tichelli , Jane F. Apperley , Elke Nekolla , Per Ljungman , Niels Jacobsen , M. van Weel , Roland Wick , Melanie Weiss , H. Grant Prentice , and Metrics 16 November 1999Volume 131, Issue 10Page: 738KeywordsBloodBone marrowCancer treatmentChemotherapyForecastingLymphomaMouthThyroidTransplantationUterus ePublished: 15 August 2000 Issue Published: 16 November 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.Loading ...
Transcriptomic analyses of esophageal cancer patients with brain metastases.
Authors: Luis E. Aguirre, Jiqiang Yao, Tania Mesa, Marek Wloch, Sean J. Yoder, Shawn Brass, Ling Cen, Jacques Fontaine, Jose Mario Pimiento, Rutika Mehta
Journal: Journal of Clinical Oncology (2022)

341 Background: Brain metastases from esophageal cancer are extremely rare with an estimated incidence of 1.7% but limited survival. Some reports highlight the rich microvascular density of such tumors and their distinctive degree of HER2, HIF1-a and EGFR expression, further emphasizing the potential role of angiogenesis in their neurotropic behavior. With this in mind, we aimed to illustrate the transcriptomic landscape of brain metastases from esophageal cancers and better understand the disease biology. Methods: Following IRB approval, we collected retrospective data on patients with a diagnosis of esophageal cancer with histology-proven brain metastases treated at our institution between 2008 and 2020. We identified 10 adequate, paired samples with available tissue for RNA extraction. Expression data was generated using NanoString TS 360 panels to characterize gene signatures of interest and analyzed using GSEA_4.1.0. Results: All 10 patients were Caucasian, 90% were male. Median age was 63 years. All had adenocarcinoma with G2-G3 histology. Median follow-up was 39.4 mos (95%CI, 27.4 to 51.4). At data cutoff, 6 patients had died. Median OS was 24.6 mos. Median time from curative surgery to CNS recurrence was 8.3 mos. Ninety percent of patients developed brain metastases within 24 mos of surgery. Median time from brain metastases to death was 4.7 mos. Almost a third of patients had HER2 positive disease. 48 gene signatures were analyzed; 5 being significantly enriched between metastatic and primary site accounting for cell cycle, DNA damage repair, MYC, mTOR signaling and immortality and stemness. Out of a pool of 760, significant overlap was seen between 12 genes across the 5 signatures of interest: POLE, LIG1, FEN1 (involved in DNA repair and replication); AURKA and PLK1 (cell proliferation and triggers for G2/M transition), BUB1 (establishment of the mitotic spindle checkpoint and chromosome congression), MCM2 and MCM4 (initiation of genome replication); BRIP1 and RAD51 (critical in homologous recombinational repair); CCNE1 (cell cycle G1/S transition) and WRAP53 (dual role as p53 regulator and protein involved in telomere elongation and DNA repair). ERBB2 was similarly enriched in primary and metastatic sites. Conclusions: These preliminary data demonstrate that the genomic basis of brain metastases in esophageal cancer goes beyond EGFR/ERBB2 signaling. A complex genomic interaction is present in brain metastases as compared to primary site that offers these cells the advantage for neurotropism. To our knowledge this is the first study attempting to illustrate genomic differences between primary and matched brain metastasis sites in esophageal cancer.
Representation of pure magnitudes in ANS
Authors: Steven Gross, William Kowalsky, Tyler Burge
Journal: Behavioral and Brain Sciences (2021)

Abstract According to Clarke and Beck (C&amp;B), the approximate number system (ANS) represents numbers. We argue that the ANS represents pure magnitudes. Considerations of explanatory economy favor the pure magnitudes hypothesis. The considerations C&amp;B direct against the pure magnitudes hypothesis do not have force.
Prevention of colorectal cancer through multiomics blood testing: The PREEMPT CRC study.
Authors: Girish Putcha, Chuanbo Xu, Aasma Shaukat, MD, MPH, Theodore R. Levin
Journal: Journal of Clinical Oncology (2022)

TPS208 Background: The USPSTF recently recommended colorectal cancer (CRC) screening for adults aged 45 to 49 years in addition to those aged 50 to 75 years. This guideline update, which increases the number of screen-eligible individuals by ̃19 million, is similar to the recommendation in 2018 by the American Cancer Society (ACS) and is based on the modeling studies that reflect rising CRC incidence rates in younger adults. Currently, only 67% of average-risk individuals over the age of 50 years are up-to-date on CRC screening, and adherence to screening is lower in younger individuals (e.g., 50-54 years). Despite the non-invasive nature of existing stool-based CRC tests, barriers remain to adoption, including a dislike for manipulating stool and a requirement for substantial navigational support. Blood tests may overcome these barriers through ease of sample collection and integration into routine blood work. Methods: Here we describe our prospective, multi-center registrational study for validating a blood-based multiomics test for average-risk CRC screening: PREEMPT CRC. Eligible participants include those aged 45-85 with no known history of CRC or colorectal adenomas who are undergoing CRC screening by colonoscopy. The target enrollment is 25,000 participants, and primary outcome measures are sensitivity for CRC and specificity for advanced colorectal neoplasia, which includes CRC and advanced adenomas. Secondary outcome measures include positive predictive value for CRC, negative predictive value for advanced colorectal neoplasia, and sensitivity for advanced adenomas. Novel recruitment methods have been implemented by combining traditional, site-based recruitment and virtual recruitment using an online web portal, coupled with mobile phlebotomy, to make participation broadly accessible, especially during the COVID-19 pandemic. Participants have been enrolled from 40 states as of August 2021, and virtual recruitment has enabled widespread participation, potentially from any zip code in the continental US. To ensure adequate representation of the intended use population, community organizations, federally qualified health centers (FQHCs), and universities have been engaged to reach underserved and minority patient populations. The study was initiated in May 2020 and to our knowledge will be the largest prospective, multi-center registrational validation study of an average-risk CRC screening test to date. Clinical trial information: NCT04369053.
Late Nephrotoxicity of Intensive Modified Program NHL-BFM-90 in Adult Poor Prognosis Patients with Diffuse Large B-Cell Lymphoma
Authors: Elena Dorokhina, Aminat Umaraskhabovna Magomedova, Sergei M Kulikov, Ludmila Biryukova, Andrey Vorobiev, Sergey Kravchenko, Valeri Savchenko
Journal: Blood (2015)
Treatment of Pernicious Anemia by a Special Diet
Authors: George R. Minot
Journal: JAMA (1983)

This paper concerns the treatment in a series of forty-five cases of pernicious anemia in which the patients were given a special form of diet. While the problem of diet in the treatment of pernicious anemia is by no means new, in our opinion its possible importance has not heretofore been generally recognized. In 1863, seven years after the publication of Addison's second, but best known, description of the disease now called pernicious anemia, Habershon<sup>1</sup>wrote concerning this condition: "Many patients at an early stage completely recover under the influence of bracing air and a nutrient and stimulating diet." Other early investigators of the disease, as Biermer<sup>2</sup>in 1872, and Pepper,<sup>3</sup>in 1875, appreciated the desirability of prescribing easily digested foods as a form of medication, but no greater emphasis was placed on the value of diet. Osler,<sup>4</sup>however, in 1885, mentioned that "cases [of pernicious
Incidental Pituitary Adenoma on MIBI Parathyroid Imaging
Authors: Jaber Abdulwahab Asiri, Sami Ahmed Kulaybi, Fatimah Ahmed Daghas
Journal: Clinical Nuclear Medicine (2021)

Abstract A 77-year-old man with a case of hyperthyroidism with high parathyroid hormone (41 pmol/L), low vitamin D, and normal thyroid-stimulating hormone. The SPECT/CT fused images confirmed the evidence of retrotracheal hyperdense mass approximately 1.0 cm of diameter below the lower pole of the right thyroid lobe with increased uptake, highly suggestive of typical parathyroid adenoma. The most significant point is that there was an incidental finding: high focal uptake in the sellar/suprasellar region corresponding to heterogenous soft tissue lesion suspicious for pituitary adenoma. According to the previous scans, nuclear medicine, CT scan, and the MRI scan indicated pituitary adenoma.
COVID‐19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings
Authors: Stephanie S. Ledbetter, Fenglong Xie, Gary Cutter, Kenneth G. Saag, Lesley Jackson, Maria I. Danila, Patrick Stewart, Michael George, William Benjamin Nowell, Ted Mikuls, Kevin Winthrop, Jeffrey R. Curtis
Journal: Arthritis & Rheumatology (2022)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Illustrated Physiology
Authors: F. T. Jung
Journal: JAMA (1964)

This book is unusual in that each page is a complete presentation, by means of diagrams and legends, of some topic in physiology. Any given page could be enlarged into a chart suitable for hanging in classroom or office. The diagrams are necessarily often schematic but deserve praise for their clarity; the accompanying text is a model of terseness. Teachers who have been frustrated by the evasiveness with which some authors approach the subjects of excretion and reproduction will find this book most helpful. It is recommended highly not only to teachers of high school and college courses but also to physicians for use in instructing patients.
The hunt for a vaccine for hepatitis C virus continues
Authors: None The Lancet Gastroenterology & Hepatology
Journal: The Lancet. Gastroenterology & hepatology (2021)

The past year has been marked by unprecedented successes in the development of several effective vaccines against SARS-CoV-2 within 12 months of discovery of the virus. Alas, the same can not be said for the development of vaccines against hepatitis C virus (HCV), discovered more than 30 years ago. Most recently, Kimberly Page and colleagues reported the results of a randomised trial of a recombinant chimpanzee adenovirus type-3 (ChAd3) vector priming vaccination followed by a recombinant modified vaccinia virus Ankara (MVA) boost that aimed to prevent chronic HCV infection in a high-risk population of recent injection drug users.